Last reviewed · How we verify
The Use of Mesenchymal Stromal Cells (MSC) in Type 1 Diabetes Mellitus in Adult Humans: Phase I Clinical Trial
Allogenic adipose derived mesenchymal stem cells will be injected into patients newly diagnosed with type 1 Diabetes Mellitus
Details
| Lead sponsor | Sophia Al-Adwan |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | 2017-02-19 |
| Completion | 2020-01 |
Conditions
- Diabetes Mellitus Type 1
Interventions
- Adipose mesenchymal cells with bone marrow mononuclear cells
Primary outcomes
- Safety of using allogenic ASC assessed by any adverse events — 6 months
Patients will be assessed for any adverse events as a result of the injection.
Countries
Jordan